This book examines trademark litigation specific to the pharmaceutical industry, where brand similarity can impact public health and regulatory compliance. It analyses deceptive similarity tests, passing off principles, interim injunction standards, and judicial approaches in pharma disputes. The authors discuss interplay between trademark law and drug regulatory frameworks, highlighting key Supreme Court and High Court judgments. Practical litigation strategies and sector-specific considerations make this book a valuable resource for IP practitioners, pharma companies, and legal researchers.







Reviews
There are no reviews yet.